Login to Your Account



TopoTarget Cutting Jobs, Conserving Cash for Belinostat

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 14, 2011
As crunch time looms for TopoTarget A/S's lead pipeline molecule belinostat, which is undergoing a pivotal Phase II trial in 129 patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), the company is cutting almost 40 percent of its Danish workforce in order to conserve cash and focus its resources.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription